SBRA
Sabra Health Care REIT, Inc. Real Estate - Healthcare Facilities Investor Relations →
Sabra Health Care REIT, Inc. (SBRA) closed at $19.74 as of 2026-09-18, trading 36.0% above its 200-week moving average of $14.51. The stock is currently moving closer to the line, down from 41.9% last week. The 14-week RSI sits at 57, indicating neutral momentum.
Trading volume is running at 1.4x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.03 ratio) is neutral — neither side is clearly dominating.
Over the past 1228 weeks of data, SBRA has crossed below its 200-week moving average 25 times. On average, these episodes lasted 20 weeks. Historically, investors who bought SBRA at the start of these episodes saw an average one-year return of +180.5%.
With a market cap of $5.0 billion, SBRA is a mid-cap stock. The company generates a free cash flow yield of 3.1%. Return on equity stands at 2.4%. The stock trades at 1.8x book value.
Share count has increased 9.0% over three years, indicating dilution.
Over the past 23.6 years, a hypothetical investment of $100 in SBRA would have grown to $16810, compared to $1378 for the S&P 500. That represents an annualized return of 24.3% vs 11.8% for the index — confirming SBRA as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been growing at a 3.4% compound annual rate, with 4 consecutive years of positive cash generation.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: SBRA vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After SBRA Crosses Below the Line?
Across 25 historical episodes, buying SBRA when it crossed below its 200-week moving average produced an average return of +297.8% after 12 months (median +14.0%), compared to +16.5% for the S&P 500 over the same periods. 56% of those episodes were profitable after one year. After 24 months, the average return was +200.5% vs +33.4% for the index.
Each line shows $100 invested at the moment SBRA crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices SBRA would reach each dislocation threshold.
Dislocation Price Levels
Prices where SBRA's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-11-04.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $18.72 | Unusually cheap — analysis point |
| Value | +1σ | $19.44 | Cheap vs. own history |
| Fair Value | +0σ | $20.22 | Historical mean behavior |
| Expensive | -1σ | $21.06 | Expensive vs. own history |
| Deep Expensive | -2σ | $21.98 | Unusually expensive — analysis point |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-03 | $0.17 | $0.15 | -10.2% |
| 2026-04-29 | $0.16 | $0.16 | +0.4% |
| 2026-02-12 | $0.16 | $0.16 | -0.5% |
| 2025-11-05 | $0.18 | $0.17 | -5.8% |
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
the write-ups I read Simply Wall St · Visual company reports and write-ups. Free tier covers five reports a month. referral
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are analysis points: prices at which the yield deviation becomes unusual enough to justify the work. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from SBRA's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. Each one is an analysis point, a reason to open the filings. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
SBRA has crossed below its 200-week MA 25 times with an average 1-year return of +180.5% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Mar 2003 | Sep 2003 | 26 | 98.4% | +4183.3% | +8304.8% |
| May 2004 | May 2004 | 1 | 9.2% | -7.3% | +276.9% |
| Jun 2004 | Jun 2004 | 1 | 2.1% | -14.6% | +247.8% |
| Jul 2004 | Aug 2004 | 4 | 8.6% | -8.7% | +270.8% |
| Oct 2004 | Nov 2004 | 2 | 1.1% | +8.6% | +240.7% |
| Nov 2004 | Dec 2004 | 4 | 5.6% | +4.2% | +257.1% |
| Feb 2005 | Oct 2005 | 34 | 19.3% | -15.3% | +236.2% |
| Nov 2005 | Nov 2005 | 1 | 0.3% | +47.1% | +242.6% |
| Dec 2005 | Mar 2006 | 12 | 15.7% | +73.3% | +268.1% |
| Oct 2008 | Oct 2008 | 1 | 1.7% | -12.6% | +128.6% |
| Nov 2008 | Feb 2009 | 12 | 24.0% | -20.1% | +134.6% |
| Feb 2009 | Jul 2012 | 177 | 63.0% | -0.6% | +182.0% |
| Sep 2015 | Oct 2015 | 1 | 0.1% | +22.2% | +115.3% |
| Oct 2015 | Jul 2016 | 38 | 30.5% | +10.5% | +113.1% |
| Oct 2016 | Nov 2016 | 4 | 9.9% | +1.2% | +116.5% |
| Aug 2017 | Aug 2017 | 3 | 5.9% | +13.2% | +95.9% |
| Sep 2017 | May 2018 | 34 | 21.7% | +16.2% | +88.4% |
| Nov 2018 | Nov 2018 | 2 | 3.4% | +28.4% | +96.6% |
| Dec 2018 | Jan 2019 | 5 | 14.3% | +19.7% | +95.8% |
| Feb 2019 | Mar 2019 | 3 | 5.7% | +20.1% | +102.4% |
| Mar 2020 | Nov 2020 | 36 | 50.6% | +87.5% | +214.6% |
| Aug 2021 | Aug 2021 | 1 | 2.3% | +13.2% | +90.3% |
| Sep 2021 | Jul 2022 | 44 | 22.9% | -4.0% | +85.6% |
| Sep 2022 | Jul 2023 | 44 | 22.8% | +6.1% | +93.3% |
| Jul 2023 | Aug 2023 | 4 | 4.2% | +40.4% | +95.5% |
| Average | 20 | — | +180.5% | — |
Frequently Asked Questions
Is SBRA below its 200-week moving average?
No. Sabra Health Care REIT, Inc. (SBRA) is currently 36.0% above its 200-week moving average of $14.51. It would need to fall to $14.51 to cross below the line.
What is SBRA's 200-week moving average price?
Sabra Health Care REIT, Inc.'s 200-week moving average is $14.51 as of 2026-09-18. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when SBRA drops below its 200-week moving average?
SBRA has crossed below its 200-week moving average 25 times in our data. On average, buying at that moment produced a one-year return of +180.5%. These dips have historically been decent entry points. These episodes lasted 20 weeks on average.
Is SBRA a good value right now?
Here's what our data says about SBRA as of 2026-09-18: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 57. Free cash flow yield is 3.1%. Return on equity is 2.4%. Price-to-book is 1.8x. This is not a buy or sell recommendation — always do your own research.
How does SBRA compare to the S&P 500?
Over the past 23.6 years, $100 invested in SBRA would have grown to $16810, compared to $1378 for the S&P 500. That's 24.3% annualized vs 11.8% for the index. SBRA has outperformed the broader market over this period.
Does SBRA pay a dividend?
Yes. Sabra Health Care REIT, Inc. currently pays a dividend yield of 608.00%.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-09-18